UK NORDIC BALTIC SUMMIT: 19-20 JANUARY 2011

DENMARK FINLAND UNITED

KINGDOMLITHUANIA SWEDEN

ESTONIA ICELAND LATVIA NORWAY

THEME: [Green Economy/Sustainable Business]

TITLE OF PRESENTATION: Synergy of IT and Life Sciences in testing for new medical treatments and control of chemical environment

Synopsis: As foreseen in regulations including REACH, more attention will be paid to identification of the properties of chemical substances and their influence on human health and the environment. Savings in time, money and animal tests are possible via computational prediction of chemical compounds and materials with predetermined properties. Example of Molcode, Ltd.

Presenter: Mati Karelson, Member of Estonian Academy of Sciences, Research and Science Advisor to the Estonian Prime Minister

Short Biography: Professor at the University of Tartu and Tallinn University of Technology, one of the most cited Estonian scientists, he has published over 190 scientific articles, monographs and monographic reviews, several patent inventions, member of Estonian R&D Council. His work is currently used in several innovative biotech and information technology companies.

CHALLENGESENVIRONMENTAL CONTROL AND HEALTH

It has been estimated that the REACH legislation alone could lead to a demand for up to 45 million laboratory animals in next 15 years

high cost time-consuming relevance to human

organism ethical problems

ALTERNATIVES ?

MOLCODE, Ltd.Computational prediction of chemical compounds and materials with predetermined properties (QSARSOFT Wizard©)

ENGINES (IT)

DATA (LS)

A combination of information technology with advancements in life sciences

ALTERNATIVES TO ANIMAL TESTSMolcode provides alternative computational data for most properties required by

REACH legislation, allowing huge savings in terms of time, money and lives (the first in the world market). Computational models validated and approved by EU Joint Research Centre.

CHALLENGESLIFE QUALITY OF AGING POPULATION

2010

SOLUTIONS ?

Sources: Tufts CSDD 2006 Outlook Report, PhRMA, ww.fda.gov

Almost 1 in 5 adults in Europe suffers from long-term pain – at least 75 million peopleSource: Pain in Europe Study, 2003

The treatment of neurodegenerative diseases costs annually European health services approximately €72 billion. Source: IP/10/431, Brussels, 15th April 2010

Existing treatments are limited, and mainly treat the symptoms, rather than addressing the cause.

Expe

nditu

res

($bi

llion

)

NEW THERAPIES FOR NEURODEGENERATIVE DISEASES

MIMETICS OF NEUROTROPHIC FACTORSIn vivo proof-of-principle of GDNF mimetics against Parkinson’s disease (6-OHDA rat model)

Drug-4 and Drug-16 are acting as efficiently or better than GDNF itself